Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors
Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 6,101.24 and Dow Jones Industrial Average DJIA falling 0.32% to 44,424.25.
William Blair cuts Charles River Labs stock rating to Market Perform
William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to Market Perform. The decision comes amid growing concerns about the company's near-term prospects,
Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $8.6 billion by market cap,
Charles River Laboratories International (NYSE:CRL) Downgraded by William Blair to Market Perform
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday,
What Analysts Are Saying About Charles River Stock
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop is evident in the current average compared to the previous average price target of $220.50.
Charles River downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street
Charles River Laboratories Stock Falls 6% on Dim FY25 Outlook
Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in morning trading. The stock is about 35% below its 52-week peak of $275.
Charles River Labs downgraded at William Blair on less early-stage R&D spending
William Blair downgraded Charles River Laboratories to market perform from outperform citing a likely decline in early-stage R&D spending from large pharmaceutical companies. Analysts Max Smock and Christine Rains said that they are concerned about the near-term outlook for the contract research organization "given our view that in light of the
Crossmark Global Holdings Inc. Sells 66 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Crossmark Global Holdings Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...
Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan
At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...
Seeking Alpha2d
CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
Hold Rating for Charles River Labs Amid Supply Chain Challenges and Mitigation Strategies
Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the ...
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
Charles River Laboratories International, Inc. CRL has introduced Apollo for CRADL (Charles River Accelerator and Development Lab), a secure cloud-based platform that enhances leading vivarium rental ...
TMCnet4d
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.